COMP <GO>
FLGT vs ABBV // ENTERPRISE SCALE & MARKET CAP
Fulgent Genetics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: FLGT 1
— ABBV 10
▲ ENTERPRISE SCALE & MARKET CAP LEADER: ABBV
LAST: $21.68 (+0.74%) • MKT CAP: $596.5M
market-cap
$596.5M
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
market-cap
$513.86B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (FLGT VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | FLGT | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 40.60% | 70.20% | -29.60 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -6.80% | 29.00% | -35.80 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -20.82% | 3.47% | -24.29 | ABBV | /fcf-yield <GO> |
| Operating Margin | -28.20% | 24.60% | -52.80 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -18.80% | 6.90% | -25.70 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 13.80% | 8.60% | +5.20 | FLGT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.44 | 5.33 | -0.89 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.3 | 65.1 | -8.80 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $596.5M | $513.86B | -$513.26B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | FLGT REV | ABBV REV | FLGT GROSS % | ABBV GROSS % | FLGT FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $322.7M | $61.16B | 40.6% | 70.2% | -$124.2M | $17.82B |
| FY 2024 | $283.5M | $56.33B | 37.8% | 70.0% | -$19.3M | $17.83B |
| FY 2023 | $289.2M | $54.32B | — | — | $27.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
FLGT // BETA —
ABBV // BETA 1.15